Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
ATMI
Advanced Therapy Manufacturing and Innovation (ATMI) Grant 2020
Overview Criteria & Project Eligibility Key Dates Apply Now Funding Principles T&C FAQ
The field of cell and gene therapy is a fast-moving, ever-changing landscape. Terumo Blood and Cell Technologies takes pride in leading the way with comprehensive manufacturing strategies, customized solutions and performance-focused products to help therapy innovators bring the next generation of cell and gene therapies within reach for more patients.


The Grant

Terumo Blood and Cell Technologies’ ATMI 2020 Grant awards up to USD $50,000 to principal investigators, scientists, researchers and clinicians exclusively from the Asia Pacific region to advance the translational research and process transfer, development, scale-up and automation of novel cell and gene therapy applications using the Quantum® Cell Expansion System.

In addition to the USD $50,000 grant, the winner will receive up to 12 disposable sets valued at USD $50,000 and one Quantum device to use during the duration of the grant project.

The project will be completed through a one-year collaborative research partnership between Terumo Blood and Cell Technologies and the successful grant applicant. The initial grant may be renewable for additional years, depending on research outcome, progress reports and amended applications.





Criteria

The grant is open to all applicants from universities, research institutes, academic centers, hospitals and biotech companies in the Asia Pacific region that meet the following criteria:
  • Principal investigator, scientists, researchers and clinicians are based in Asia Pacific countries and possess extensive research experience and peer-reviewed publications in their field of study
  • Protocol is established and proof of concept has been achieved with the existing technology
  • Researchers have the relevant scientific and technical background necessary to direct and commit to the grant project throughout the grant period
  • Laboratory facility has essential cell culture equipment and an aseptic workstation
  • Submission demonstrates scientific novelty and impact of the technology transfer and application to Quantum


Project Eligibility

Proposal submissions will be considered in the following areas:
  • Expansion of pluripotent stem cells
  • Expansion of immune cells, such as natural killer (NK) cells
  • Expansion of genetically modified immune cells
  • Large-scale production of exosomes
  • Viral vector production (suspension and adherent)
  • Other novel technological application feasible with Quantum

  • Proposals using human cell types are preferred.

Key Dates



September 2020 to 17 November 2020
Submissions accepted

Through November 2020
Proposal review

17 December 2020
Shortlist notification

15 January 2021
Consultation sessions* completed

31 January 2021
Grant winner announcement


Dates are subject to change without prior notice.
*One to two meetings may be arranged with shortlisted applicants to better understand the novelty, feasibility and potential scope for the proposed grant project.

Apply Now

Applications will be accepted beginning on 17 September and must be received by 17 November 2020, 23:59 Singapore time (GMT+8).

  1. Download the Application Guide for submission guidance.
  2. Download the ATMI Grant Application form.
  3. Complete the form.
  4. Submit the completed file along with supporting attachments to apacctt@terumobct.com.
Direct any additional questions about the ATMI grant application process to apacctt@terumobct.com.






Register Now for a Pre-Application Webinar


Led by industry expert Dr. Yu Lei, CEO of UniCAR-Therapy Bio-Medicine Technology Co., and Terumo Blood and Cell Technologies’ field application scientists by appointment:
  • Gain insight from users who are automating their novel cell and gene therapy applications with Quantum
  • Learn about Quantum’s unique bioreactor features that support process developments
  • Participate in a live Q&A session that will aid in drafting your grant proposal

Register early!


Early registrants will enjoy live webinar sessions with Dr. Yu Lei and our field application scientists. Later registrants will view a recorded webinar and participate in a live Q&A with our field application scientists.

Yes, I would like to receive future communications about Terumo Blood and Cell Technologies

I confirm that I have read and agree to the Terumo Blood and Cell Technologies Privacy Policy regarding the use of information.*

Funding Principles

The grant awards up to USD $50,000 to the winner and project for one year. One Quantum device and up to 12 disposable sets shall be provided to the successful applicant for the grant project’s duration. The initial grant may be renewable for additional years, depending on research outcome, progress reports and amended applications.

The grant is strictly used for the funding of reagents and consumables incurred in the grant project. Additional details on grant terms and reporting requirements will be made available to recipients upon award. The grant is subject to the execution of a collaborative research agreement between Terumo Blood and Cell Technologies and the successful applicant. Other terms and conditions may apply.


Terms and Conditions

The following terms and conditions apply for every submission:
  • Submission must demonstrate scientific novelty and impact of technology, process and/or application transfer to Quantum.
  • Submissions must be made in English.
  • The winner must complete and sign the award contract within 30 days. Failure to accept the contract may result in loss of the award, in which case the runner-up will be considered.
  • Projects are expected to be completed within one year and may be extended on a case-by-case basis, subject to further application and approval.
  • Terumo Blood and Cell Technologies reserves the right to approve or decline any application. Applications are reviewed by an internal review committee. Award of grant in any one cycle does not imply that subsequent support will be awarded without further application and approval.

Frequently Asked Questions



Q1: Which countries and regions in the Asia Pacific region are considered?
Applications from the following Asia Pacific countries and regions that meet the eligibility criteria will be considered and reviewed based on merits: Australia, Bangladesh, Brunei, Cambodia, China, Fiji, India, Indonesia, Laos, Malaysia, Maldives, Mongolia, Myanmar, Nepal, New Zealand, Papua New Guinea, Philippines, Pakistan, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste and Vietnam.


Q2: What are the grant terms and details?
The ATMI Grant 2020 awards up to USD $50,000 to the successful applicant and project over a one-year period. One Quantum system and up to 12 disposable sets will be provided to the successful applicant for the duration of the grant project. The initial grant may be renewable for additional years depending on research outcome, progress reports and amended applications.

The grant can only be used for the funding of reagents and consumable incurred in the grant project.

Additional details on grant terms and reporting requirements will be made available to recipients upon award. The grant is subject to the execution of a collaborative research agreement between Terumo Blood and Cell Technologies and the successful applicant. Other terms and conditions may apply.


Q3: What is the review and decision-making process?
Only proposals submitted within the application period and meeting the eligibility criteria will be accepted for review. These proposals are internally reviewed by the Terumo Blood and Cell Technologies Medical Affairs department. The assessment criteria include the following:
  • Scientific and clinical merit of proposal
  • Track record of applicant
  • Focus on novel scientific and technological areas as listed in Project Eligibility

Applicants whose proposals receive positive reviews in the first stage of the reviewing process may be shortlisted for further consult and discussion to evaluate the novelty, feasibility, and potential scope of study. This process will take approximately four to six weeks, from the last day of grant application submission to the final award. Terumo Blood and Cell Technologies will follow up with a collaborative research agreement to be signed within 30 days by the grant winner.


Q4: I am not a current user of Quantum. Am I still eligible to apply for the ATMI Grant 2020?
Yes, you may apply for the ATMI Grant 2020 if you satisfy the eligibility criteria. Applicants need not be current users of the Quantum Cell Expansion System.

We are seeking to fund and collaborate with scientists and technology experts who are interested in using Quantum to translate and scale novel cell and gene therapy applications or processes toward a clinically relevant quality and scale.


Q5: I wish to learn more about Quantum before submitting my proposal. Who can I contact for more information?
Thank you for your interest! Please submit your query to apacctt@terumobct.com. You can also learn about Quantum at https://www.terumobct.com/quantum.


Q6: What is the arrangement for a successful grant recipient who does not have a Quantum system installed in their lab facility?
A Quantum system will be provided to the successful grant recipient for the duration of the grant project. Training will be provided by our regional Field Application Scientist.


Q7: What are the commitments expected of me and my team if we win the ATMI Grant 2020?
The grant is subject to a collaborative research agreement between Terumo Blood and Cell Technologies and the successful applicant. The study milestones, timeline and reporting requirements will be aligned with recipients upon award. The development of data and materials achieved from the collaborative research (e.g., peer reviewed publication, posters, conference or webinar presentations, and/or press release, etc.) is also a key deliverable.

Applicants will provide a brief study plan, timeline and goals as part of their submission.







​​​​​

{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }} {{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}